SecBot SecBot
SECBOTREPLAY Home › Report › SLS

SLS · SELLAS reported Q3 2026 net loss of $10.1M ($0.05 per share), in line…

SELLAS Life Sciences Group, Inc. · 8-K filed Nov 12, 2026 at 16:07 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 12, 2026 at 16:07 ET

SELLAS reported Q3 2026 net loss of $10.1M ($0.05 per share), in line with the $-0.05 consensus. Cash and equivalents stood at $134.7M. The key catalyst is the upcoming topline readout of the Phase 3 REGAL trial of GPS in AML, expected this month, and preliminary Phase 2 SLS009 data expected in Q4 2026.

  • Q3 2026 net loss of $10.1M, or $0.05 per share, vs $6.8M loss ($0.06) in Q3 2025
  • Cash and cash equivalents of $134.7M as of September 30, 2026
  • 80th event in Phase 3 REGAL trial of GPS occurred in October 2026; topline results expected this month
  • 40 of 80 patients enrolled in Phase 2 trial of SLS009 in newly diagnosed AML; preliminary topline data expected Q4 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access